Preliminary safety and efficacy results with an intermittent schedule of the PI3kδ inhibitor ME-401 alone or in combination with rituximab for B-cell malignancies Meeting Abstract


Authors: Zelenetz, A. D.; Soumerai, J. D.; Jagadeesh, D.; Reddy, N.; Stathis, A.; Asch, A. S.; Salman, H. S.; Kenkre, V. P.; Jhangiani, H.; Iasonos, A.; Krish, P.; Ghalie, R. G.; Pagel, J. M.
Abstract Title: Preliminary safety and efficacy results with an intermittent schedule of the PI3kδ inhibitor ME-401 alone or in combination with rituximab for B-cell malignancies
Meeting Title: 60th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 132
Issue: Suppl. 1
Meeting Dates: 2018 Dec 1-4
Meeting Location: San Diego, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2018-11-29
Language: English
ACCESSION: WOS:000454842800093
PROVIDER: wos
Notes: Meeting Abstract: 2893 -- Source: Wos
MSK Authors
  1. Alexia Elia Iasonos
    179 Iasonos
  2. Andrew D Zelenetz
    554 Zelenetz